Oct 12, 2018 12:30AM Chugai Releases Disease Awareness Anime about Rheumatoid Arthritis in Multiple Languages Emphasizing Importance of Early Detection/Treatment and Care by Specialists

Oct 4, 2018 09:00PM Chugai's HEMLIBRA® Receives Regulatory Approval from U.S. FDA for Hemophilia A Without Inhibitors

Aug 30, 2018 01:00AM Results of Global Phase III Study with Chugai's HEMLIBRA® for Hemophilia A Without Inhibitors Published in the New England Journal of Medicine

Jul 26, 2018 03:00AM Announcement of Business Expansion of Chugai Pharmabody Research Pte. Ltd., Chugai's Research Subsidiary

Jul 26, 2018 02:30AM Chugai Enters into Comprehensive Partnership Agreement with Preferred Networks

May 21, 2018 05:44AM Chugai Presents Results of Two Pivotal Phase lll Studies for its Bispecific Antibody HEMLIBRA® at WFH 2018

Apr 17, 2018 01:00AM Chugai's HEMLIBRA® Receives Breakthrough Therapy Designation from U.S. FDA for Hemophilia A Without Factor VIII Inhibitors

Feb 27, 2018 09:20PM Chugai's HEMLIBRA® Approved by European Commission in Hemophilia A with Inhibitors

Jan 28, 2018 06:30PM Chugai's HEMLIBRA® Gains Positive CHMP Opinion in Hemophilia A with Inhibitors

Dec 21, 2017 01:30AM EU Follows US and Approves Chugai's ALK Inhibitor "Alecensa®" as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer

Dec 7, 2017 02:45AM Chugai's Emicizumab Every Four Weeks Showed Positive Interim Results in Phase III Study

Nov 20, 2017 03:29AM Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study

Nov 16, 2017 06:30PM Chugai's HEMLIBRA® Receives the World's First Regulatory Approval from FDA for Hemophilia A with Inhibitors

Nov 8, 2017 01:00AM Chugai's ALK Inhibitor "Alecensa®" Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in the US

Oct 4, 2017 09:20PM Chugai's Bispecific Antibody "ERY974" Results of Preclinical Study Published in Science Translational Medicine

Aug 24, 2017 01:00AM Chugai's Emicizumab Receives Priority Review Designation by FDA for Hemophilia A with Inhibitors

Jun 5, 2017 07:30PM Data of Chugai's Alecensa® Presented at the American Society of Clinical Oncology on Global Phase III ALEX Study

May 11, 2017 12:51AM Results of the J-ALEX Study for Chugai's Alecensa® are Published in "The Lancet" Online

Apr 10, 2017 03:42AM Chugai's Alecensa® Met Its Primary Endpoint in the ALEX Study

Mar 29, 2017 08:01PM Chugai - A*STAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund

Feb 27, 2017 01:00AM Chugai's ALK Inhibitor "Alecensa®" Approved in Taiwan

Dec 22, 2016 04:27AM Chugai's Bispecific Antibody "Emicizumab" for Hemophilia A Meets Primary Endpoint in Phase lll Study

Oct 5, 2016 01:00AM Chugai's ACTEMRA®/RoACTEMRA® Receives Breakthrough Therapy Designation from US FDA for Giant Cell Arteritis

Oct 4, 2016 01:00AM Chugai's Alecensa® Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer

Jul 27, 2016 10:30PM Chugai's Emicizumab Showed Continued Benefits in Patients with Hemophilia A

Jul 20, 2016 07:30PM Chugai and Galderma Announce Global License Agreement for Nemolizumab (CIM331), Novel Biologic for Skin Diseases

May 25, 2016 10:30PM Chugai's Bispecific Antibody "ACE910/Emicizumab" Phase l Data in Patients with Hemophilia A Published in The New England Journal of Medicine Online

May 18, 2016 09:00PM Chugai to Present Japanese Phase III Results on Alecensa® at ASCO

Mar 5, 2016 12:30PM Chugai Announces Phase II Global Study Results of Nemolizumab (CIM331) in Late-breaking Research Forums at AAD

Feb 10, 2016 04:49AM Chugai's ALK Inhibitor "Alecensa®" Trial Stopped Early for Benefit

Dec 14, 2015 01:34AM Chugai's ALK Inhibitor "Alecensa®" Accelerated Approval in Three Months after Priority Review Designation in the US

Nov 30, 2015 03:00AM Chugai Pharma Marketing Changed Its Corporate Name to Chugai Pharma Europe

Oct 1, 2015 08:10PM Company Profile for Chugai Pharmaceutical Co., Ltd.

Sep 10, 2015 02:00AM Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo®) in the UK by Chugai Pharma UK Ltd.

Sep 9, 2015 01:00AM Chugai's ALK Inhibitor "Alectinib," New Drug Application Submitted for ALK Positive Advanced Non-Small Cell Lung Cancer in the United States

Sep 4, 2015 01:00AM Chugai's Bispecific Antibody "ACE910" for the Treatment of Hemophilia A Designated as a Breakthrough Therapy by the US FDA